We are analyzing https://link.springer.com/article/10.1007/s40744-018-0102-x.

Title:
A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases | Rheumatology and Therapy
Description:
Tocilizumab (TCZ) is the first humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody approved for the treatment of patients with rheumatoid arthritis (RA), Castleman’s disease, polyarticular and systemic juvenile idiopathic arthritis, and, most recently, giant cell arteritis as well as for the treatment of chimeric antigen receptor T cell therapy-induced cytokine release syndrome. The global clinical development program for TCZ provides a wealth of clinical data on intravenous TCZ, and more recent studies in patients with RA have provided evidence characterizing the role of intravenous TCZ as monotherapy in early disease and led to the introduction of a subcutaneous formulation of TCZ. In addition, recently published open-label extension and observational studies continue to support the long-term efficacy and safety of TCZ in both clinical trial and real-world settings. Given the involvement of IL-6-mediated signaling in inflammatory disorders, TCZ is also being investigated in other immunological diseases. In particular, a phase 2 trial on the safety and efficacy of subcutaneous TCZ in adults with systemic sclerosis shows clinically relevant improvements in skin sclerosis and lung function in these patients. Another anti-IL-6 receptor agent, sarilumab, targeting the IL6 receptor alpha subunit, was recently approved for the treatment of patients with RA, although long-term data for this biologic are not yet published. In this article we review the placement of TCZ in current treatment guidelines; recent clinical trial data, including quality of life in patients with RA; recent updates to the TCZ safety profile; recent investigations of TCZ in other immunological diseases; and the clinical development of other novel IL-6-targeted agents.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

patients, tcz, pubmed, google, scholar, article, tocilizumab, arthritis, cas, treatment, trial, rheumatoid, disease, study, clinical, phase, mtx, efficacy, monotherapy, safety, response, week, results, rheumatol, mgkg, data, therapy, improvements, inadequate, rheum, studies, trials, weeks, treated, remission, receptor, rates, sarilumab, reported, dis, central, ann, analysis, randomized, doubleblind, antibody, demonstrated, compared, tczsc, years,

Topics {✒️}

gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm569150 janus-activated kinase-signal transducer anti-il-6-receptor monoclonal antibody including human anti-il-6r alpha das28-esr-defined remission rates car t-cell therapies th1 t-cell responses anti-il-6r nanobody vobarilizumab anti-interleukin-6 receptor antibody disease-modifying antirheumatic drugs anti-interleukin-6 receptor nanobody decreases b-cell hyperactivity jak janus-activated kinase das28-esr-defined remission anti-il-6 receptor antibody das28-defined remission rates suppressed c-reactive protein conventional treatment-refractory adult-onset open-label extension study lte long-term extension anti-il-6 receptor agent roactemra 20 mg/ml concentrate real-world observational cohorts chimeric antigen receptor achieved tocilizumab-free remission graft-versus-host disease 8 mg/kg body weight haq-di score improvements real-world data show anti-il-6r biologics article rubbert-roth trans-signaling cascades involving tcz-iv 4 mg/kg increased das28-crp-defined improvements andrea rubbert-roth u-act-early study real-world data sources u-act-early trial il-6 signaling-targeted biologics long-term extension studies article download pdf anti-tnf-alpha failure humanized anti-interleukin-6 short-term symptomatic efficacy single-arm pilot study higher relapse-free survival tumor necrosis factor das28-defined remission anti-il-6 antibody corticosteroid-free tocilizumab monotherapy

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases
         description:Tocilizumab (TCZ) is the first humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody approved for the treatment of patients with rheumatoid arthritis (RA), Castleman’s disease, polyarticular and systemic juvenile idiopathic arthritis, and, most recently, giant cell arteritis as well as for the treatment of chimeric antigen receptor T cell therapy-induced cytokine release syndrome. The global clinical development program for TCZ provides a wealth of clinical data on intravenous TCZ, and more recent studies in patients with RA have provided evidence characterizing the role of intravenous TCZ as monotherapy in early disease and led to the introduction of a subcutaneous formulation of TCZ. In addition, recently published open-label extension and observational studies continue to support the long-term efficacy and safety of TCZ in both clinical trial and real-world settings. Given the involvement of IL-6-mediated signaling in inflammatory disorders, TCZ is also being investigated in other immunological diseases. In particular, a phase 2 trial on the safety and efficacy of subcutaneous TCZ in adults with systemic sclerosis shows clinically relevant improvements in skin sclerosis and lung function in these patients. Another anti-IL-6 receptor agent, sarilumab, targeting the IL6 receptor alpha subunit, was recently approved for the treatment of patients with RA, although long-term data for this biologic are not yet published. In this article we review the placement of TCZ in current treatment guidelines; recent clinical trial data, including quality of life in patients with RA; recent updates to the TCZ safety profile; recent investigations of TCZ in other immunological diseases; and the clinical development of other novel IL-6-targeted agents.
         datePublished:2018-03-03T00:00:00Z
         dateModified:2018-03-03T00:00:00Z
         pageStart:21
         pageEnd:42
         license:https://creativecommons.org/licenses/by/4.0
         sameAs:https://doi.org/10.1007/s40744-018-0102-x
         keywords:
            Interleukin-6
            Rheumatoid arthritis
            Tocilizumab
            Rheumatology
            Orthopedics
            General Practice / Family Medicine
            Internal Medicine
            Quality of Life Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40744-018-0102-x/MediaObjects/40744_2018_102_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40744-018-0102-x/MediaObjects/40744_2018_102_Fig2_HTML.gif
         isPartOf:
            name:Rheumatology and Therapy
            issn:
               2198-6584
               2198-6576
            volumeNumber:5
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Healthcare
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Andrea Rubbert-Roth
               affiliation:
                     name:Kantonsspital St Gallen
                     address:
                        name:Kantonsspital St Gallen, St Gallen, Switzerland
                        type:PostalAddress
                     type:Organization
                     name:Kantonsspital St. Gallen
                     address:
                        name:Clinic for Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Daniel E. Furst
               affiliation:
                     name:University of California, Los Angeles
                     address:
                        name:University of California, Los Angeles, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Washington
                     address:
                        name:University of Washington, Seattle, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Florence
                     address:
                        name:University of Florence, Florence, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jan Michael Nebesky
               affiliation:
                     name:F. Hoffmann–La Roche
                     address:
                        name:F. Hoffmann–La Roche, Basel, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Angela Jin
               affiliation:
                     name:Genentech
                     address:
                        name:Genentech, South San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Erhan Berber
               affiliation:
                     name:Genentech
                     address:
                        name:Genentech, South San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases
      description:Tocilizumab (TCZ) is the first humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody approved for the treatment of patients with rheumatoid arthritis (RA), Castleman’s disease, polyarticular and systemic juvenile idiopathic arthritis, and, most recently, giant cell arteritis as well as for the treatment of chimeric antigen receptor T cell therapy-induced cytokine release syndrome. The global clinical development program for TCZ provides a wealth of clinical data on intravenous TCZ, and more recent studies in patients with RA have provided evidence characterizing the role of intravenous TCZ as monotherapy in early disease and led to the introduction of a subcutaneous formulation of TCZ. In addition, recently published open-label extension and observational studies continue to support the long-term efficacy and safety of TCZ in both clinical trial and real-world settings. Given the involvement of IL-6-mediated signaling in inflammatory disorders, TCZ is also being investigated in other immunological diseases. In particular, a phase 2 trial on the safety and efficacy of subcutaneous TCZ in adults with systemic sclerosis shows clinically relevant improvements in skin sclerosis and lung function in these patients. Another anti-IL-6 receptor agent, sarilumab, targeting the IL6 receptor alpha subunit, was recently approved for the treatment of patients with RA, although long-term data for this biologic are not yet published. In this article we review the placement of TCZ in current treatment guidelines; recent clinical trial data, including quality of life in patients with RA; recent updates to the TCZ safety profile; recent investigations of TCZ in other immunological diseases; and the clinical development of other novel IL-6-targeted agents.
      datePublished:2018-03-03T00:00:00Z
      dateModified:2018-03-03T00:00:00Z
      pageStart:21
      pageEnd:42
      license:https://creativecommons.org/licenses/by/4.0
      sameAs:https://doi.org/10.1007/s40744-018-0102-x
      keywords:
         Interleukin-6
         Rheumatoid arthritis
         Tocilizumab
         Rheumatology
         Orthopedics
         General Practice / Family Medicine
         Internal Medicine
         Quality of Life Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40744-018-0102-x/MediaObjects/40744_2018_102_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40744-018-0102-x/MediaObjects/40744_2018_102_Fig2_HTML.gif
      isPartOf:
         name:Rheumatology and Therapy
         issn:
            2198-6584
            2198-6576
         volumeNumber:5
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Healthcare
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Andrea Rubbert-Roth
            affiliation:
                  name:Kantonsspital St Gallen
                  address:
                     name:Kantonsspital St Gallen, St Gallen, Switzerland
                     type:PostalAddress
                  type:Organization
                  name:Kantonsspital St. Gallen
                  address:
                     name:Clinic for Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Daniel E. Furst
            affiliation:
                  name:University of California, Los Angeles
                  address:
                     name:University of California, Los Angeles, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Washington
                  address:
                     name:University of Washington, Seattle, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Florence
                  address:
                     name:University of Florence, Florence, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jan Michael Nebesky
            affiliation:
                  name:F. Hoffmann–La Roche
                  address:
                     name:F. Hoffmann–La Roche, Basel, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Angela Jin
            affiliation:
                  name:Genentech
                  address:
                     name:Genentech, South San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Erhan Berber
            affiliation:
                  name:Genentech
                  address:
                     name:Genentech, South San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Rheumatology and Therapy
      issn:
         2198-6584
         2198-6576
      volumeNumber:5
Organization:
      name:Springer Healthcare
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Kantonsspital St Gallen
      address:
         name:Kantonsspital St Gallen, St Gallen, Switzerland
         type:PostalAddress
      name:Kantonsspital St. Gallen
      address:
         name:Clinic for Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
         type:PostalAddress
      name:University of California, Los Angeles
      address:
         name:University of California, Los Angeles, Los Angeles, USA
         type:PostalAddress
      name:University of Washington
      address:
         name:University of Washington, Seattle, USA
         type:PostalAddress
      name:University of Florence
      address:
         name:University of Florence, Florence, Italy
         type:PostalAddress
      name:F. Hoffmann–La Roche
      address:
         name:F. Hoffmann–La Roche, Basel, Switzerland
         type:PostalAddress
      name:Genentech
      address:
         name:Genentech, South San Francisco, USA
         type:PostalAddress
      name:Genentech
      address:
         name:Genentech, South San Francisco, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Andrea Rubbert-Roth
      affiliation:
            name:Kantonsspital St Gallen
            address:
               name:Kantonsspital St Gallen, St Gallen, Switzerland
               type:PostalAddress
            type:Organization
            name:Kantonsspital St. Gallen
            address:
               name:Clinic for Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Daniel E. Furst
      affiliation:
            name:University of California, Los Angeles
            address:
               name:University of California, Los Angeles, Los Angeles, USA
               type:PostalAddress
            type:Organization
            name:University of Washington
            address:
               name:University of Washington, Seattle, USA
               type:PostalAddress
            type:Organization
            name:University of Florence
            address:
               name:University of Florence, Florence, Italy
               type:PostalAddress
            type:Organization
      name:Jan Michael Nebesky
      affiliation:
            name:F. Hoffmann–La Roche
            address:
               name:F. Hoffmann–La Roche, Basel, Switzerland
               type:PostalAddress
            type:Organization
      name:Angela Jin
      affiliation:
            name:Genentech
            address:
               name:Genentech, South San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Erhan Berber
      affiliation:
            name:Genentech
            address:
               name:Genentech, South San Francisco, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Kantonsspital St Gallen, St Gallen, Switzerland
      name:Clinic for Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
      name:University of California, Los Angeles, Los Angeles, USA
      name:University of Washington, Seattle, USA
      name:University of Florence, Florence, Italy
      name:F. Hoffmann–La Roche, Basel, Switzerland
      name:Genentech, South San Francisco, USA
      name:Genentech, South San Francisco, USA

External Links {🔗}(356)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.42s.

LINK . SPRINGER . COM {}